A team of Michigan State University scientists has genetically sequenced two species of poisonous mushrooms, discovering that they can theoretically produce billions of compounds through one molecular assembly line. This may open the door to efficiently tackling some lethal diseases.

Cornell engineers hope that clean water runs deep. They have developed a new technique to test for a wide range of micropollutants in lakes, rivers and other potable water sources that vastly outperforms conventional methods.

“Water quality monitoring is conventionally done by narrowly investigating one or a few contaminants at a time. We aimed to develop an analytical method that would be as broad as possible,” said Damian Helbling, assistant professor of civil and environmental engineering. Helbling and Amy Pochodylo, M.S. ’14, published their research as the cover story in the journal Environmental Science: Water Research & Technology.

Drugs that contain one or more fluorine atoms tend to be more stable, more powerful, and easier for the body to absorb. For those reasons, drug developers would like to be able to incorporate fluorine or a fluorine-containing unit known as trifluoromethyl into new experimental drugs, but this has been very difficult to do.

Now, a team of chemists at MIT and Boston College has discovered a new type of catalyst that can incorporate a trifluoromethyl group within a variety of organic molecules. The availability of these exceptionally efficient and selective catalysts should allow researchers to rapidly generate potential new fluorinated drugs, including antibiotics and anticancer agents, for testing.

If your New Year’s resolution was to exercise more in 2017, chances are you’ve already given up or you’re on the verge of doing so. To reach your goal, you may want to consider joining a gym, based on the results of a new study from a team of Iowa State University researchers.

Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer. In a new paper published this week in Cancer Cell, Mayo Clinic researchers provide genetic evidence that Ect2 drives lung adenocarcinoma tumor formation.

When epidemiological data are scarce, social media and Internet reports can be reliable tools for forecasting infectious disease outbreaks, according to a study led by an expert in the School of Public Health at Georgia State University.

“Our study offers proof of concept that publicly available online reports released in real-time by ministries of health, local surveillance systems, the World Health Organization and authoritative media outlets are useful to identify key information on exposure and transmission patterns during epidemic emergencies,” the researchers said. “Our Internet-based findings on exposure patterns are in good agreement with those derived from traditional epidemiological surveillance data, which can be available after considerable delays.”

LA JOLLA—Normally when we think of viruses, from the common cold to HIV, we want to boost people’s immunity to fight them. But for scientists who develop therapeutic viruses (to, for example, target cancer cells or correct gene deficiencies) a more important question is: How do we keep people’s natural immune responses at bay? In these cases, an overenthusiastic immune response actually undermines the therapy.

LA JOLLA—Just as an invasive weed might need nutrient-rich soil and water to grow, many cancers rely on the right surroundings in the body to thrive. A tumor’s microenvironment—the nearby tissues, immune cells, blood vessels and extracellular matrix—has long been known to play a role in the tumor’s growth.

A team of scientists led by prof. Adrian Liston (VIB–KU Leuven) and prof. Isabelle Meyts (UZ Leuven – KU Leuven) were able to characterize a new genetic immunodeficiency resulting from a mutation in a gene named STAT2. This mutation causes patients to be extremely vulnerable to normally mild childhood illnesses such as rotavirus and enterovirus. Prof. Liston’s comprehensive analysis of the genetic defect allows clinicians to provide children with the proper therapies before illnesses prove fatal. The findings of the research have been published in the Journal of Allergy and Clinical Immunology.

Lugano, Switzerland – Biosimilars create opportunities for sustainable cancer care, says the European Society for Medical Oncology (ESMO) in a position paper published in ESMO Open. The document outlines approval standards for biosimilars, how to safely introduce them into the clinic, and the potential benefits for patients and healthcare systems.